Introduction: Informed consent involves understanding the risks and benefits of trial enrollment. This is challenging in the phase I setting since true quantitative information is never known. We therefore performed an analysis of published radiation oncology (RO) phase I trials emphasizing patient outcomes. To our knowledge, no such systemic analysis has previously been published.
American Society for Therapeutic Radiation Oncology (ASTRO) 52nd Annual Meeting October 31 - November 4, San Diego, CA
Glass, C.; Den, R. B.; Dicker, A. P.; and Lawrence, Y. R.
"Toxicity of Phase I Radiation Oncology Trials: Worldwide Experience,"
Bodine Journal: Vol. 3
, Article 31.
Available at: http://jdc.jefferson.edu/bodinejournal/vol3/iss1/31